Detalhe da pesquisa
1.
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Immunity
; 47(6): 1083-1099.e6, 2017 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29246442
2.
CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer.
Cancer Res
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38635884
3.
Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.
Sci Adv
; 8(29): eabm8780, 2022 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35857848
4.
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations.
Cancer Res
; 82(19): 3435-3448, 2022 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35930804
5.
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry.
Nat Commun
; 12(1): 5906, 2021 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625563
6.
Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer.
EMBO Mol Med
; 12(8): e11987, 2020 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32672423
7.
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITFhigh /AXLlow melanoma.
Pigment Cell Melanoma Res
; 32(2): 280-291, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30277012
8.
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Sci Transl Med
; 11(510)2019 09 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-31534020
9.
RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.
Cancer Cell
; 36(1): 68-83.e9, 2019 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257073
10.
Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer.
Cell Rep
; 25(13): 3545-3553.e2, 2018 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-30590030
11.
Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts.
Clin Cancer Res
; 10(3): 1180-91, 2004 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14871998
12.
Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
PLoS One
; 10(9): e0139074, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26413866
13.
Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix.
Thromb Haemost
; 90(5): 921-9, 2003 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-14597989
14.
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Cancer Cell
; 20(6): 715-27, 2011 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-22169110
15.
A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.
Cancer Res
; 70(20): 8036-44, 2010 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20807807
16.
Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
PLoS One
; 3(7): e2734, 2008 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-18628967
17.
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Mol Cell
; 20(6): 963-9, 2005 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-16364920